Biotech & Pharma Attendees at the Oligonucleotide Analytical Development & CMC Conference
Join a highly curated audience of global biotech, mid-sized pharma, and cutting-edge oligonucleotide specialists advancing analytical development and CMC strategies. Attending companies span innovative biotech disruptors, established pharmaceutical leaders, CDMOs, and key technology providers—collectively shaping the future of oligonucleotide therapeutics across discovery, scale-up, and commercialisation.
This is not a junior audience. You will be in the room with Heads of Analytical Development, Directors of CMC, VPs of Technical Operations, and Senior Leaders across Process Development, Manufacturing, and Regulatory Affairs. The attendee profile reflects a clear pattern: decision-makers responsible for pipeline progression, technology adoption, and manufacturing strategy, supported by highly specialised technical experts driving execution.
What makes this audience uniquely powerful is its cross-functional depth. Organisations are bringing together stakeholders from analytical development, CMC, and manufacturing to solve shared bottlenecks—from impurity characterisation and method validation to scale-up challenges and regulatory readiness. If you are not in the room, you are missing direct access to the teams actively defining how oligonucleotide therapeutics are developed, validated, and brought to market.
